iRhythm Technologies, a digital health company focused on creating solutions that detect, predict, and prevent disease, has received the CE mark under MDR for its long-term ambulatory cardiac monitor – the Zio monitor ECG System.
shutterstock.com / spaxiax
558934465
Cardiac monitoring
The Zio monitor ECG System secured its CE mark based on compliance to EU MDR standards of performance, quality, safety, and efficacy, along with the body of clinical evidence supporting Zio in detecting potential cardiac arrhythmias.
Zio monitor builds on the high performance of Zio XT that, together with its enhanced long term continuous cardiac monitoring service, provides an elevated end-to-end experience to patients with potential arrhythmias and demonstrates 99% patient compliance with prescribed wear times. The new Zio monitor is thinner, lighter, and smaller compared to Zio XT to provide a more inconspicuous wear experience. Early clinical and patient experience in the United States has shown that Zio monitor has even better wear times and analysable ECG. Furthermore, the certification incorporates CE mark for the ZEUS (Zio ECG Utilization Software) System, iRhythm’s advanced deep-learned AI algorithm which supports the capture and analysis of ECG data recorded by Zio monitor.
Quentin Blackford, iRhythm president and chief executive officer, said: “The EU MDR is arguably one of the most stringent regulatory frameworks for product approvals globally that ensures medical devices meet the rigorous standards for healthcare technologies. Receiving this CE mark certification for our Zio monitor and ZEUS system reflects our team’s commitment to delivering the highest quality services as we seek to drive better health outcomes and more equitable access for patients around the globe. Our teams did an excellent job to effectively convey the significant body of clinical study evidence underlying our Zio services and our deep-learned AI algorithm as key differentiators. With improved clinical accuracy compared to existing traditional Holter monitoring, we look forward to introducing our innovative technology to many more patients in Europe.”
